Novye vozmozhnosti v strategii lecheniya bol'nykh s idiopaticheskoylegochnoy gipertenziey: antagonist retseptorov endotelina bozentan
- Authors: Martynyuk TV1, Chazova IE1
-
Affiliations:
- Issue: Vol 5, No 4 (2008)
- Pages: 25-29
- Section: Articles
- URL: https://journals.eco-vector.com/2075-082X/article/view/28830
- DOI: https://doi.org/10.26442/SG28830
- ID: 28830
Cite item
Full Text
Abstract
References
- Диагностика и лечение легочной гипертензии. Российские рекомендации, 2007.
- Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2006; 31: 407-15.
- Мартынюк Т.В., Чазова И.Е., Масенко В.П. и др. Эндотелиальная дисфункция у больных с легочной гипертензией. Кардиология. 1997; 10: 25-9.
- Galie N, Manes A, Branzi A. The endothelin system in pulmonary hypertension. Cardiovasc Res 2004; 61: 227-37.
- Stewart DJ, Levy RD, Cernacek P. Increased plasma endothelin-1 in primary pulmonary hypertension: marker or mediator of disease ? Ann Intern Med 1991; 114: 464-9.
- Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-9.
- Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-36.
- Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
- McLaughlin VV, Sitbon O, Rubin L et al. The effect of first-line Bosentan on survival of patients with primary pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: A442.
- Sitbon O, Badesch DB, Channick RN. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124: 247-54.
- Galie N, Rubin LJ, Hoeper MM et al. Treatment of patients with mildly symptomatic pulmonary hypertension with bosentan (EARLY study): a double-blind, andomised controlled trial. Lancet 2008; 371: 2093-100.